Pitavastatin vs Testosterone
FDA Approved vs FDA Approved
compatible Researched · 90% No interaction concerns. Supraphysiological testosterone modestly worsens lipid profiles, and pitavastatin helps maintain healthier lipid levels during testosterone cycles or TRT. Pitavastatin does not affect testosterone metabolism, aromatization, or anabolic activity. The lack of CYP3A4 involvement is a specific advantage here, as testosterone and many of its esters undergo hepatic metabolism through CYP pathways.
Molecular Data
Pitavastatin Testosterone
Weight 421.46 Da 288.42 Da (base)
Half-life ~12 hours ~8 days (cypionate)
Type Synthetic statin (C25H24FNO4) Steroid hormone (C19H28O2)
Key Benefits
Pitavastatin
01 Minimal CYP450 metabolism — does not interact with CYP3A4, making it ideal for users taking multiple compounds
02 Lowest risk of new-onset diabetes among all statins, supported by the LIVES study and J-PREDICT trial data
03 LDL reductions of 38-45% at standard doses (2-4 mg/day)
04 More robust HDL-raising effect (5-15%) compared to other statins in the class
05 12-hour half-life supports convenient once-daily dosing
06 Favorable safety profile with low incidence of muscle-related side effects
07 Compatible with CYP3A4 inhibitors and inducers that would alter levels of other statins
08 Effective at counteracting AAS-induced lipid disturbances without adding to drug interaction burden
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
Pitavastatin
1-4 mg/day / Once daily
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
Pitavastatin
Myalgia and muscle discomfort (approximately 3-5% of users) — generally mild and less frequent than with lipophilic statins
Headache
Minimal liver enzyme elevation — typically transient and clinically insignificant
Back pain
Constipation or diarrhea
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
Active liver disease or unexplained persistent elevations in hepatic transaminases
Known hypersensitivity to pitavastatin or any excipients
Pregnancy and breastfeeding (Category X — statins are teratogenic)
Concomitant use with cyclosporine (significantly increases pitavastatin levels via OATP1B1 inhibition)
Concomitant use with lopinavir/ritonavir or atazanavir/ritonavir combinations
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
Pitavastatin Testosterone
Status FDA Approved FDA Approved
References 5 studies 5 studies
Latest 2023 June 2023
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.